HOLX HOLOGIC INC

NEUTRAL Impact: 9/10 8-K
Horizon months Filed Apr 7, 2026 Processed 2mo ago SEC 0001193125-26-144632
Killer combo: M&A completed + management change
Latest settled — T+1d
HOLX ▲ 0.00% at T+1d
NEUTRAL call ✗ call lost 0.00% · α vs SPY -2.54% · entry $76.01 → $76.01
Next anchor: T+5d due 2mo ago
Entry anchored
Apr 6, 05:08 PM ET
via Databento tick
T+1d
0.00%
call 0.00% · α -2.54%
$76.01
settled 2mo ago
T+5d
call — · α —
due 2mo ago
T+20d
call — · α —
due 6w ago
T+60d
call — · α —
in 17d

Price Chart

Loading chart...

Executive Summary

Hologic completed its acquisition by Blackstone and TPG, becoming a private company. The deal closed at $76 per share in cash plus a contingent value right (CVR) worth up to $3 per share based on future revenue milestones. The company was delisted from Nasdaq, all directors and the CEO resigned, and Joe Almeida was appointed as the new CEO.

Key Financial Metrics

Deal Value
$17.3B

Actionable Insight

Traders should note that Hologic is no longer publicly traded, eliminating liquidity for existing shareholders. The CVR provides potential upside based on future revenue performance, but investors should monitor Hologic's Breast Health segment revenue to assess the likelihood of milestone achievement. The leadership change to Joe Almeida, an experienced MedTech executive, may influence future strategic direction.

Key Facts

  • Hologic was acquired by Blackstone and TPG for $76 per share in cash plus a CVR worth up to $3 per share, totaling up to $79 per share.
  • The acquisition closed on April 7, 2026, making Hologic a private company.
  • Hologic's stock was delisted from Nasdaq following the acquisition.
  • All directors and CEO Stephen MacMillan resigned, with Joe Almeida appointed as the new CEO.
  • The CVR payments are contingent on achieving specific revenue milestones for Hologic's Breast Health business in fiscal years 2026 and 2027.

Financial Impact

Total transaction value of up to $79 per share, with $76 in cash and up to $3 in contingent payments. The total cash consideration was approximately $17.3 billion.

market_capshare_priceliquiditydebt

Risk Factors

  • CVR payments are contingent on future revenue performance and may not be realized.
  • Loss of public market liquidity for former shareholders.
  • Integration risks under new private ownership and leadership.

Market Snapshot

Exchange
Nasdaq
Sector
X-Ray Apparatus & Tubes & Related Irradiation Apparatus

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-144632
Document: d135035dex32.htm0001193125-26-144632
Document: d135035d8k.htm0001193125-26-144632
Document: d135035dex991.htm0001193125-26-144632
Document: d135035dex31.htm0001193125-26-144632
Document: 0001193125-26-144632-index-headers.html0001193125-26-144632
Document: 0001193125-26-144632-index.html0001193125-26-144632
Document: 0001193125-26-144632.txt0001193125-26-144632
5 reports for HOLX
Performance horizon
Filters
Rows
Reports for HOLX — sortable, filterable
Type Now
Apr 17, 2026
8w ago
15-12G
NEUTRAL ★ 7/10
awaiting T+1
Apr 13, 2026
9w ago
EFFECT
NEUTRAL ★ 3/10
awaiting T+1
Apr 7, 2026
9w ago
8-K
NEUTRAL ★ 9/10
$76.01 $76.01· 0.00%▼ −2.54%
Apr 6, 2026
9w ago
8-K
NEUTRAL ★ 7/10
$76.01 $76.01· 0.00%▼ −0.06%
Feb 28, 2026
15w ago
Institutional Cluster
MIXED ★ 6/10
$75.45 $75.46▲ +0.01%▲ +0.93%
Showing 5 of 5

US Market Status

Market Closed — Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access